INO
Inovio Pharmaceuticals, Inc.NASDAQHealthcare$1.13-35.06%ClosedMarket Cap: $60.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
21.99
P/S
926.75
EV/EBITDA
-0.31
DCF Value
$0.07
FCF Yield
-146.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
-2189.0%
Operating Margin
-132871.3%
Net Margin
-130000.0%
ROE
-353.4%
ROA
-114.3%
ROIC
-259.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-17.5M | $3.8M | $0.05 | — |
| FY 2025 | $65.3K | 100.0% | $-86.8M | $-84.9M | $-1.81 | — |
| Q3 2025 | $0.00 | NaN% | $-21.2M | $-45.5M | $-0.87 | — |
| Q2 2025 | $0.00 | -Infinity% | $-23.1M | $-23.5M | $-0.61 | — |
| Q1 2025 | $65.3K | 100.0% | $-25.1M | $-19.7M | $-725.11 | — |
| Q4 2024 | $117.0K | -563.1% | $-20.4M | $-19.4M | $-0.70 | — |
| FY 2024 | $217.8K | 100.0% | $-112.4M | $-107.3M | $-3.95 | — |
| Q3 2024 | $0.00 | NaN% | $-27.3M | $-25.2M | $-894.28 | — |
| Q2 2024 | $100.8K | -722.4% | $-33.2M | $-32.2M | $-1.19 | — |
| Q1 2024 | $0.00 | NaN% | $-31.5M | $-30.5M | $-1.31 | — |
| Q4 2023 | $102.7K | -70.7% | $-27.4M | $-25.0M | $-1.10 | — |
| FY 2023 | $832.0K | 100.0% | $-143.9M | $-135.1M | $-6.09 | — |